This study is designed to determine whether levodopa will lead to an improvement in the development and tremor in children with Angelman syndrome (AS).
It has been suggested that levodopa, a medication that is usually used to treat Parkinson disease in adults, may help children with AS in their overall development and reduce the tremor that some of them have.
If levodopa is found to be beneficial for children with AS, this could lead to a new treatment for AS.
Funding Source – FDA-OOPD
Full Title of Study: “A Phase 2 Randomized Placebo-Controlled Trial of Levodopa in Angelman Syndrome”
- Study Type: Interventional
- Study Design
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Primary Purpose: Treatment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Study Primary Completion Date: July 2015
Levodopa is a prodrug that "delivers" dopamine to the brain. It is usually given with carbidopa, a peripheral decarboxylase inhibitor, to increase the bioavailability of levodopa. Animal studies have suggested that levodopa can reverse the excess phosphorylation of some enzymes involved in synaptic and neuronal function, including calcium/calmodulin-dependent kinase type 2 (CaMKII).
Recently, it was shown that excess phosphorylation of CaMKII may be responsible for some of the neurological deficits seen in Angelman syndrome. Therefore, it is hypothesized that levodopa may lead to an improvement in the neurodevelopment and abnormal movements (e.g. tremors) in children with Angelman syndrome.
Although many children have used levodopa for a variety of medical conditions over the last 30 years, it has not been approved by the Food and Drug Administration (FDA) for use in children, and it has not been formally studied in children with Angelman syndrome.
Therefore, the purpose of this study is to find out whether levodopa will lead to an improvement in the development and in the tremor in children with AS.
- Drug: Levodopa
- Levodopa/Carbidopa (4:1) Dosages are based on levodopa. Subjects randomized to the levodopa arm will receive a levodopa dose of 5 mg/kg/day in the first 2 weeks of the study, a levodopa dose of 10 mg/kg/day in the second 2 weeks of the study, and a levodopa dose of 15 mg/kg/day (up to a maximum of 800 mg per day) for the remaining duration of the study. Levodopa/Carbidopa is a combined formulation that will be dispensed as capsules. It should be taken 3 times a day.
- Drug: Placebo Oral Capsule
- The placebo contains excipients similar to those in the active drug, but it does not contain levodopa or carbidopa.
Arms, Groups and Cohorts
- Experimental: Levodopa
- Levodopa is prescribed as a combination of levodopa/carbidopa (4:1) to reduce the peripheral side effects. The dosage used was 15 mg/kg/day in 3 divided doses.
- Placebo Comparator: Placebo
- The placebo contains excipients similar to those in the active drug, but it does not contain levodopa or carbidopa, so it is not expected to have any effect.
Clinical Trial Outcome Measures
- Bayley Cognitive Age Equivalent at 1 Year
- Time Frame: 12 months
- Presence of Tremors
- Time Frame: 1 year
Participating in This Clinical Trial
1. Age between 4 years and 12 years (i.e., before the 13th birthday)
2. Molecular confirmation of the diagnosis of AS, which may include abnormal methylation studies or UBE3A mutation analyses – only subjects with a molecular diagnosis will be allowed to enroll
3. Not on LD, CD, or any dopamine agonists in the 2 weeks prior to participation
1. Co-morbid disorders that may be associated with developmental or cognitive delays
2. Poorly controlled seizures – An average of more than 2 clinical seizures per month in the 12 months prior to enrollment.
3. Use of medications that may interact with LD/CD including atypical antipsychotics (aripiprazole, asenapine, iloperidone, olanzapine, paliperidone, risperidone, ziprasidone), monoamine oxidase inhibitors (isocarboxazid, phenelzine, selegiline, tranylcypromine), or phenytoin within the last 14 days, or other investigational interventions within the past 3 months
4. Presence of cardiovascular disease or instability, respiratory disease, liver disease, peptic ulcer disease, renal impairment, or hematological disorders
Gender Eligibility: All
Minimum Age: 4 Years
Maximum Age: 12 Years
Are Healthy Volunteers Accepted: No
- Lead Sponsor
- Wen-Hann Tan
- Rady Children’s Hospital, San Diego
- Provider of Information About this Clinical Study
- Sponsor-Investigator: Wen-Hann Tan, Attending Physician in Genetics – Boston Children’s Hospital
- Overall Official(s)
- Wen-Hann Tan, BMBS, Principal Investigator, Boston Children’s Hospital
- Lynne M. Bird, MD, Principal Investigator, Rady Children’s Hospital, San Diego
- Steven A. Skinner, MD, Principal Investigator, Greenwood Genetic Center
- Carlos A. Bacino, MD, Principal Investigator, Baylor College of Medicine
- Anne Slavotinek, MD, Principal Investigator, University of California, San Francisco
- Cary Fu, MD, Principal Investigator, Vanderbilt University Medical Center
- Logan Wink, M.D, Principal Investigator, Children’s Hospital Medical Center, Cincinnati
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.